Montelair 5mg Chewable Tablet

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

MONTELUKAST SODIUM

Boleh didapati daripada:

HOVID BERHAD

INN (Nama Antarabangsa):

MONTELUKAST SODIUM

Unit dalam pakej:

30tablet Tablets

Dikeluarkan oleh:

HOVID BERHAD

Risalah maklumat

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
MONTELAIR TABLET
Montelukast Chewable Tablet (5mg), Montelukast Film-coated tablet (10
mg)
1
WHAT IS IN THIS LEAFLET
1.
What Montelair is used for
2.
How Montelair works
3.
Before you use Montelair
4.
How to take Montelair
5.
While you are using Montelair
6.
Side effects
7.
Storage and Disposal of Montelair
8.
Product description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of revision
WHAT MONTELAIR IS USED FOR
This medicine is used to:
•
prevent and treat asthma in adults
•
relieve day and night symptoms of
seasonal
allergic
rhinitis
(hay
fever).
HOW MONTELAIR WORKS
This medicine is a leukotriene receptor
antagonist. It blocks substances in your
lungs
that
narrows
and
swells
your
airways.
The
substance
is
called
leukotriene.
By blocking leukotrienes, your asthma
symptoms will improve and this helps
prevents asthma attacks. Montelair also
improves hay fever symptoms.
BEFORE YOU USE MONTELAIR
_- When you must not take it _
Do not take this medicine if:
•
you
or
your
child
is
allergic
to
montelukast
or
any
of
the
excipients
•
you or your child are already taking
any
medicine
containing
montelukast
•
you or your child is/are galactose
intolerance,
have
Lapp
lactase
deficiency
or
glucose-galactose
malabsorption
•
your child is younger than 2 years
old.
_- Before you start to take it _
Tell your doctor if:
•
your child has phenylketonuria, the
inability to process the part of the
protein called phenylalanine
•
you
are
pregnant,
plan
to
get
pregnant
•
you
are
breastfeeding
or
plan
to
breastfeed.
_- Taking other medicines _
Talk to your doctor or pharmacist if you
are taking any other medicines in any
form
including
any
that
you
buy
or
obtained without a prescription.
Some
medicines
interfere
with
the
active ingredients in Montelair.
They include:
•
other
medicines
containing
montelukast
•
phenobarbital
•
phenytoin
•
rifampicin.
Other interactions not stated may occur.
Talk to your doctor or pharmacist if you
have any other concern

Ciri produk

VIMON07-4var (MY)
DESCRIPTION
MONTELAIR 10 MG FILM-COATED TABLET: Square, beige film-
coated
tablet,
shallow
convex,
bevel-edged
and
“HD”
embossed on one face.
MONTELAIR 5 MG CHEWABLE TABLET: 10 mm, round, pink
mottled uncoated tablet, bevel edged, shallow convex faces,
“HD” embossed and scored on the same face.
COMPOSITION
MONTELAIR 10 MG FILM-COATED TABLET: Montelukast Sodium
which is equivalent to Montelukast 10 mg.
MONTELAIR 5 MG CHEWABLE TABLET: Montelukast Sodium
which is equivalent to Montelukast 5 mg.
PHARMACODYNAMICS
The cysteinyl leukotrienes (LTC
4
, LTD
4
, LTE
4
) are potent
inflammatory
eicosanoids
released
from
various
cells
including
mast
cells
and
eosinophils.
These
important
pro-asthmatic mediators bind to cysteinyl leukotriene (CysLT)
receptors. The CysLT type-1 (CysLT
1
) receptor is found in the
human airway (including airway smooth muscle cells and
airway macrophages) and on other pro-inflammatory cells
(including
eosinophils
and
certain
myeloid
stem
cells).
CysLTs have been correlated with the pathophysiology of
asthma and allergic rhinitis. In asthma, leukotriene-mediated
effects
include
bronchoconstriction,
mucous
secretion,
vascular permeability, and eosinophil recruitment. In allergic
rhinitis, CysLTs are released from the nasal mucosa after
allergen exposure during both early- and late-phase reactions
and
are
associated
with
symptoms
of
allergic
rhinitis.
Intranasal challenge with CysLTs has been shown to increase
nasal airway resistance and symptoms of nasal obstruction.
Montelukast is a potent, orally active compound that significantly
improves parameters of asthmatic inflammation. Based on
biochemical and pharmacological bioassays, it binds with high
affinity and selectivity to the CysLT
1
receptor (in preference to
other pharmacologically important airway receptors such as the
prostanoid, cholinergic, or ß-adrenergic receptor). Montelukast
potently inhibits physiologic actions of LTC
4
, LTD
4
and LTE
4
at the CysLT
1
receptor without any agonist activity.
PHARMACOKINETICS